Esketamine and pulsed radiofrequency for treating trigeminal neuralgia from shingles

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness and safety of combining esketamine with pulsed radiofrequency (PRF) treatment for patients suffering from acute or subacute zoster-associated trigeminal neuralgia. Participants will receive standardized treatment alongside these interventions to assess pain relief over a one-month period. The goal is to find a safe and effective option for patients who have not responded to conventional therapies. The study focuses on individuals with significant pain levels and recent herpes zoster infections affecting the trigeminal nerve.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \>18 years;
2. History of HZ within the last three months;
3. Lesions located in the trigeminal nerve or its branches innervated regions；
4. Numeric Rating Scale (NRS) pain score≥4 (NRS, 0 = no pain, 10= worst possible pain) with pharmacotherapy;
5. Planned to perform CT-guided PRF treatment of the Gasserian ganglion .

Exclusion Criteria:

1. Obstructive sleep apnoea syndrome;
2. Those who receive other invasive treatments, such as spinal cord stimulation;
3. A history of systemic immune diseases, organ transplantation, or cancers;
4. A history of severe cardiopulmonary, hepatic or renal dysfunction;
5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
6. Comorbid hyperthyroidism or phaeochromocytoma;
7. Recent history of drug abuse;
8. Having contraindications to esketamine;
9. Communication difficulties.

Withdrawal criteria

1. Lost to follow-up during the study;
2. Not perform the planned operation;
3. Receiving other treatment regimes during the study period;
4. Not suitable for continuing the study for emerging severe comorbidities or special physiological changes during the study;
5. Voluntary withdrawal from the study.

Where it's running

• Beijing Tiantan Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: Fang Luo, M.D. — Beijing Tiantan Hospital
• Study coordinator: Fang Luo, M.D.
• Email: 13611326978@163.com
• Phone: +86 13611326978

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reduced vaccine response to GSK Shingrix in people with SLE

  This study tests whether people with systemic lupus erythematosus (SLE) have a different antibody response to the shingles vaccine Shingrix compared with similar people without autoimmune disease.

  Recruiting Seoul National University Hospital · Seoul · NCT07636044

• Recombinant Zoster Vaccine with ZFA01 Adjuvant in Adults 40+

  A two-part study tests a recombinant herpes zoster vaccine in healthy adults aged 40 and older to see if it boosts immune responses and is safe.

  Recruiting at 2 sites Phase 1/2 Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Guangxi, Nanning and 1 other locations · NCT07920172

• How long the live shingles vaccine protects you

  This will see if the live attenuated shingles vaccine keeps adults from the original Phase III trial protected against herpes zoster for up to six years after vaccination.

  Recruiting Jiangsu Province Centers for Disease Control and Prevention · Nanjing, Jiangsu · NCT07585370

• Recombinant zoster (Shingrix) to see if it lowers new dementia diagnoses in people 76 and older in Finland.

  This trial will test whether the Shingrix shingles vaccine lowers the chance of a new dementia diagnosis in people aged 76 or older who live in Finland.

  Recruiting at 8 sites Phase 4 GlaxoSmithKline · Espoo and 7 other locations · NCT07502560

• Erector spinae plane block versus transcutaneous radiofrequency for postherpetic neuralgia

  This project will see if erector spinae plane block or transcutaneous radiofrequency works better to reduce pain in adults with postherpetic neuralgia.

  Recruiting Diskapi Teaching and Research Hospital · Ankara · NCT07400640

• Lyophilized shingles mRNA vaccine safety and immune response

  This trial will test a lyophilized mRNA vaccine to see if it is safe and produces immune responses in adults aged 40 years and older.

  Recruiting Phase 1/2 Sinovac Biotech Co., Ltd · Xinjiang · NCT07400003

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.